These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9499446)

  • 1. Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study.
    Bajetta E; Celio L; Di Leo A; Bartoli C; Pilotti S; Leutner M; Bono A; Ferrari L; Buzzoni R; Zilembo N; De Candis D; Moglia D
    Int J Oncol; 1998 Apr; 12(4):853-8. PubMed ID: 9499446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
    Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
    Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
    Lundgren S; Søreide JA; Lea OA
    Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
    Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
    Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response.
    Makris A; Powles TJ; Allred DC; Ashley S; Ormerod MG; Titley JC; Dowsett M
    Breast Cancer Res Treat; 1998 Mar; 48(1):11-20. PubMed ID: 9541185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen impairs prepubertal mammary development and alters expression of estrogen receptor α (ESR1) and progesterone receptors (PGR).
    Tucker HL; Parsons CL; Ellis S; Rhoads ML; Akers RM
    Domest Anim Endocrinol; 2016 Jan; 54():95-105. PubMed ID: 26619291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
    Breast Cancer; 2015 Jan; 22(1):71-8. PubMed ID: 23479208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
    Detre SI; Ashley S; Mohammed K; Smith IE; Powles TJ; Dowsett M
    Cancer Prev Res (Phila); 2017 Mar; 10(3):171-176. PubMed ID: 28100469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
    Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
    Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative assessment of proliferative activity and hormonal receptor status in carcinoma of the breast: a comparison of needle aspiration and needle-core biopsies to the surgical specimen.
    Railo M; Nordling S; Krogerus L; Sioris T; von Smitten K
    Diagn Cytopathol; 1996 Sep; 15(3):205-10. PubMed ID: 8955602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer.
    Ferrandina G; Ranelletti FO; Larocca LM; Maggiano N; Fruscella E; Legge F; Santeusanio G; Bombonati A; Mancuso S; Scambia G
    Clin Cancer Res; 2001 Sep; 7(9):2656-61. PubMed ID: 11555576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.
    Kumaki N; Umemura S; Tang X; Saito Y; Suzuki Y; Tokuda Y
    Breast Cancer; 2011 Apr; 18(2):98-102. PubMed ID: 21290265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.